A Radomized Trial of Epirubicin & Cyclophosphamide vs. Epirubicin & Paclitaxel in the Treatment of Women With Metastatic Breast Cancer
OBJECTIVES: I. Compare the activity and toxicity of epirubicin and cyclophosphamide with
that of epirubicin and paclitaxel in patients with metastatic breast cancer.
OUTLINE: Patients are randomized to receive either epirubicin and cyclophosphamide or
epirubicin and paclitaxel. Each drug combination is given every 3 weeks for 6 courses in the
absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 704 patients will be accrued for this study.
Primary Purpose: Treatment
James Carmichael, MD, PhD
Nottingham City Hospital
United States: Federal Government